

**MINUTES OF TECHNICAL EVALUATION COMMITTEE MEETING FOR TENDER NO.-
BMSIC/DRUGS/21-09 (SHORT TENDER FOR RATE CONTRACT AND SUPPLY OF DRUGS
FOR DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 05th November 2021

Venue: BMSICL Conference Hall.

The **Technical Evaluation Committee Meeting for Tender No. BMSIC/DRUGS/21-09** was held on **05th November 2021** under the Chairmanship of Dr. Navin Chandra Prasad, Director in Chief, Department of Health, GoB. The other committee members present in the meeting were:

1. Sh. Ram Ishwar, Joint Secretary, Department of Health, GoB
2. Sh. Rajani Kant, CGM (Supply Chain), BMSICL.
3. Sh. Sudhir Kumar, GM (Procurement), BMSICL.
4. Sh. Suman Prasad Sah, Deputy Secretary-cum-I/C Procurement, SHSB.
5. Sh. Ramendra Kumar, OSD (Drug & Equipment), BMSICL.
6. Sh. Navneet Kumar, DGM (Drugs), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/21-09.
2. Tender floated date- 23/09/2021.
3. Last date of submission of Online bids- 07/10/2021.

3. The Tender has been floated on e-proc Portal for 06 (Six) Drugs.

4. Total 06 bidders were found to have successfully submitted their bids on the e-proc online system. The submission status of hard copy of the technical bids including the tender fee and Earnest Money Deposit (EMD), till the stipulated time was found as following: -

Sl No.	Name of the Firm	Online submission status of bids on E-Proc	Requisite Tender fee of Rs 10,000/- receipt Status	Requisite Amount of EMD receipt Status	Remarks
1	M/s Cipla Limited	Ok	Received	Received	Ok
2	M/s Mylan Laboratories Limited	Ok	Received	Received	Ok
3	M/s Mylan Pharmaceuticals Private Limited	Ok	Received	Received	Ok
4	M/s Natco Pharma Limited	Ok	Received	Received	Ok
5	M/s Samarth Life Sciences Pvt. Ltd.	Ok	Received	Received	Ok
6	M/s Bharat Serums and Vaccines Limited	Ok	Received	Received	Ok
7	M/s Vim Meditech Pvt .Ltd.	Ok	Not Received	Not Received	Not Ok
8	M/s Sytco Inc.	Not Ok	Not Received	Not Received	Not Ok
9	M/s Jubilant Generics Ltd.	Not Ok	Not Received	Not Received	Not Ok
10	M/s Unirose Pharma Pvt. Ltd.	Not Submitted	NA	NA	Not Ok

5. The firm M/s Sytco Inc. & M/s Jubilant Generics Ltd. neither submitted the Earnest Money Deposit (EMD) & Tender Fee nor considered by the online e-proc system. The firm M/s Vim Meditech Pvt .Ltd. not submitted Earnest Money Deposit (EMD) & Tender Fee .The firm Unirose Pharma Pvt. Ltd. has not applied on online e-proc system. It was therefore unanimously decided by the TEC in its meeting dated 08-10-2021 to return the hardcopy of Unirose Pharma Pvt. Ltd. Accordingly, it was unanimously decided to recommend for considering only those above mentioned 06 bidders (Sl. No. 01 to 06) who have successfully submitted their bids online as well as EMD & Tender fee, for further technical evaluation process.

6. The item wise bid received status was as follows:

S.N.	Name of the Product	Participating Firms	No. of Bids
1	Enoxaparin Injection IP 40mg/0.4ml Injection 0.4 ml Pre-filled Syringe	Bharat Serums and Vaccines Limited	2
		Samarth Life Sciences Pvt. Ltd.	
2	Methyl Prednisolone Acetate Injection 40mg/ml Injection Vial	No Bidder participated	0
3	Tocilizumab Injection 400mg Vial	No Bidder participated	0
4	Remdesivir Injection 100 mg Vial	Cipla Limited	2
		Mylan Laboratories Limited	
5	Amphotericin B Deoxycholate Injection 50mg/Vial	Bharat Serums and Vaccines Limited	3
		Mylan Pharmaceuticals Private Limited	
		Samarth Life Sciences Pvt. Ltd.	
6	Posaconazole Injection 300mg/vial 300mg/vial	Mylan Pharmaceuticals Private Limited	2
		Natco Pharma Limited	

7. The summary of Bid received status was as follows:

1. No Bids received for **02** items.
2. Multiple Bids received for **04** items.

8. It was therefore unanimously decided by the TEC in its meeting dated 08-10-2021 to recommend for Re-tender of Drugs at NIT SN- 2 & 3 (**02** Drugs) due to no bid condition and to evaluate the bids for **those 04 Drugs** (NIT SN- 1, 4, 5 & 6) for which multiple bid has been received.

9. The Preliminary Evaluation of technical bids of the above-mentioned bidding firms was done by the assigned team including Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the website of BMSICL and Claims/objections were invited vide notice no. 5347 dated 11.10.2021.

10. After perusal of the clarification received in the light of that notice, the 03 (Three) bidders namely M/s Bharat Serums and Vaccines Limited, M/s Samarth Life Sciences Pvt. Ltd. & M/s Natco Pharma Limited were found technically qualified and since they were having valid rate contract with BMSICL, hence factory inspection was not recommended for these firms. However, factory inspection was

recommended for remaining three firms and their five following units, i.e., M/s Cipla Limited (**Unit-I-Nitin Lifescience Ltd. & Unit-II-Kamla Lifescience**), M/s Mylan Laboratories Limited (**Unit-I-Mylan Laboratories Limited & Unit-II- Gland Pharma Ltd.**) & M/s Mylan Pharmaceuticals Private Limited (**Unit-I- MSN Laboratories Pvt. Ltd.**) in order to verify the documents submitted by them *inter alia* the other points of verification.

11. Accordingly, the Physical verification of the manufacturing units of above mentioned firms was conducted by the team of Drug Inspectors deputed at BMSICL. After perusal of the Factory Inspection report, the drug wise technical evaluation findings were recorded as follows:

S.N.	NIT S.N.	Name of the Product	Participating Firms	Status after factory inspection	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	1	Enoxaparin Injection IP 40mg/0.4ml Injection 0.4 ml Pre-filled Syringe	Bharat Serums and Vaccines Limited	Not Applicable	Technically Qualified	Ok
			Samarth Life Sciences Pvt. Ltd.	Not Applicable	Technically Qualified	Ok
2	4	Remdesivir Injection 100 mg Vial	Cipla Limited	<p>Unit I- Nitin Life Science Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department as per clause 3(k) not submitted, hence not ok.</p> <p>Unit II- Kamla Lifescience Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department as per clause 3(k) submitted.</p> <p>Cipla Limited :</p> <p>Annexure-X as per clause 2(d) not submitted, hence not ok.</p>	Technically Disqualified	<p>Unit I- Nitin Life Science Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority from Drugs Control Department as per clause 3(k) not submitted, hence not ok.</p> <p>Unit II- Kamla Lifescience Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department as per clause 3(k) submitted.</p> <p>Cipla Limited :</p> <p>Annexure-X as per clause 2(d) not submitted, hence not ok.</p>

			Mylan Laboratories Limited	<p>Unit I-</p> <p>Mylan Laboratories Limited-Self Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department not submitted.</p> <p>Unit II- Gland Pharma-Loan Licence Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department not submitted.</p>	Technically Disqualified	<p>Unit I-</p> <p>Mylan Laboratories Limited-Self Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department as per clause 3(k) not submitted, hence not ok.</p> <p>Unit II- Gland Pharma-Loan Licence Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority form Drugs Control Department as per clause 3(k) not submitted, hence not ok.</p>
3	5	Amphotericin B Deoxycholate Injection 50mg/Vial	Bharat Serums and Vaccines Limited	Not Applicable	Technically Qualified	Ok
			Mylan Pharmaceuticals Private Limited	Not Applicable	Technically Disqualified	Import License for three years accompanied by their invoices, statement as per clause 3(g) & an affidavit (with stamp) sworn before First Class Magistrate/ Notary for Maximum Production Capacity as per clause 3(k) not submitted, hence not ok.
			Samarth Life Sciences Pvt. Ltd.	Not Applicable	Technically Qualified	Ok

4	6	Posaconazole Injection 300mg/vial	Mylan Pharmaceuticals Private Limited	Unit-I- MSN Laboratories Pvt. Ltd. Market standing certificate & Maximum Production Capacity Certificate (section wise) not submitted.	Technically Disqualified	Unit-I- MSN Laboratories Pvt. Ltd. Market standing certificate as per clause 3(h) & Maximum Production Capacity Certificate (section wise) as per clause 3(k) not submitted, hence not ok.
			Natco Pharma Limited	Not Applicable		Ok

12. As per the above comparative chart 03 (Three) bidders namely M/s Bharat Serums and Vaccines Limited, M/s Samarth Life Sciences Pvt. Ltd. & M/s Natco Pharma Limited were found technically qualified notwithstanding their product wise qualification status as mentioned above. It was therefore unanimously decided to recommend for opening of the financial bids of the technically qualified bidders on e-proc Portal. It was also unanimously decided to Re-tender for the product at NIT Sl. N. 4 (Remdesivir Injection 100 mg Vial) due to no firm qualified technically & NIT Sl. N. 6 (Posaconazole Injection 300mg/vial) due to single firm qualified technically.

13. The meeting thus concluded with a vote of thanks.

Sd/-
(Navneet Kumar)
DGM (Drugs), BMSICL, Patna.

Sd/-
(Ramendra Kumar)
OSD (D & E), BMSICL.

Sd/-
(Suman Prasad Sah)
Deputy Secretary-cum-I/C Procurement,
SHSB.

Sd/-
(Sudhir Kumar)
GM (Procurement), BMSICL, Patna

Sd/-
(Rajani Kant)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
(Ram Ishwar)
Joint Secretary, Department of Health, GoB

Sd/-
(Dr. Navin Chandra Prasad)
Director in Chief, Health Dept.
Govt. of Bihar.